Ultime notizie per RPAR Risk Parity ETF (ARCA:RPAR)

Basic Materials

Energy

Technology

Industrials

Financial Services

Consumer Cyclical

Healthcare

Consumer Defensive

Communication Services

Utilities

Real Estate

Other

The Fund is an actively-managed exchange-traded fund (ETF) that seeks to achieve its investment objective primarily by investing across a variety of asset classes, including exposure to global equity securities, U.S. Treasury securities, and commodities. The Funds investment adviser seeks to invest the Funds assets to achieve exposures similar to those of the Advanced Research Risk Parity Index (the RPAR Index), a rules-based index created by Advanced Research Investment Solutions, LLC (ARIS).

First American Government Obligations Fund Class X

Vanguard Total Stock Market ETF

Spdr Gold Minishares Trust

Vanguard Msci Emergi

Vanguard FTSE Developed Markets Index Fund ETF

RPAR Risk Parity ETF

The Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), an <a href="https://www.benzinga.com/etfs">ETF that mirrors the tech-heavy Nasdaq 100 index</a>, is charging through May like it had a triple shot of AI-fueled espresso, with two old friends to thank: Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
With only one trading day remaining in the month, QQQ has gained almost 10%, and is set to post its strongest monthly performance since 2023. The surge has been powered by Nvidia&#8217;s solid earnings and Tesla&#8217;s resurgence.
Nvidia, QQQ&#8217;s second-largest position, got the ball rolling with <a href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong">fiscal Q1 results that did not disappoint</a>. The chip giant reported adjusted EPS of $0.96 and revenue of $44.1 billion. The shares surged 4.5% after hours on Wednesday, pulling QQQ 0.6% higher. On Thursday, NVDA is up 4.04% and QQQ, 0.4% as of 1 p.m ET.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45675006/nvidia-stock-has-significant-upside-as-ai-godfather-jensen-huang-delivers-another-robust-quarter">Nvidia Stock Has &#8216;Significant Upside&#8217; As AI &#8216;Godfather&#8217; Jensen Huang Delivers Another &#8216;Robust Quarter&#8217;</a>
Although Q2 revenue guidance was a bit short of the mark at $45 billion, factoring in a potential $8 billion decline from continued U.S. export bans on its H20 chips in China, Nvidia&#8217;s data center division, the jewel of its AI crown, brought in a whopping $39.1 billion, with solid demand in evidence.
Meanwhile, Tesla has <a href="https://www.benzinga.com/25/05/45668119/tesla-rides-a-bullish-wave-as-byd-slashes-prices-whos-really-winning-the-ev-war">accelerated its way back into investors&#8217; favor</a>. Stock is up almost 24% for May, the strongest month since November 2024 for the EV manufacturer. QQQ, whose top 10 holdings include Tesla, is obviously riding the momentum.
The reversal comes as Elon Musk completes his time with the Department of Government Efficiency (DOGE). Investors welcomed Musk&#8217;s renewed emphasis on Tesla&#8217;s AI and full self-driving prospects, and Wedbush&#8217;s Dan Ives hailed Tesla as the &#8220;most undervalued AI play&#8221; on the market.
ETF Ecosystem: Nvidia And Tesla Everywhere
Nvidia isn&#8217;t just juicing QQQ; it&#8217;s ubiquitous. According to Etf.com, over 625 U.S.-listed ETFs own NVDA stock. Among those ETFs is the VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>), which carries a substantial 21% weightage. That ETF also benefited from Nvidia&#8217;s earnings day.
Tesla&#8217;s resurgence, though less pervasive in ETF land, is proving to have a significant impact for QQQ due to its large-cap weighting and effect on the Nasdaq 100&#8217;s performance.
Bottom Line: QQQ&#8217;s High-Octane May
With AI darlings and EV titans firing on full cylinders, QQQ is racing towards a record May close. Nvidia&#8217;s earnings momentum and Tesla&#8217;s narrative reversal have made the ideal cocktail of tech optimism.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/05/45676519/bullion-to-blockchain-why-gen-z-may-never-buy-a-gold-etf">Bullion To Blockchain: Why Gen Z May Never Buy A Gold ETF</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

Tech

ETFs

NVDA

QQQE

TSLA

NVDA, TSLA Turbocharge QQQ Surge Toward Best Month Since 2023

Shares of autonomous driving company Pony.ai Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) fell another 7.53% to $17.07 Thursday afternoon, extending Wednesday's 15% drop despite no fresh company-specific news. The selloff comes after a sharp rally earlier this week fueled by the company's announcement of a major expansion into Dubai.
What To Know: On Tuesday, Pony.ai <a href="https://www.benzinga.com/news/global/25/05/45628748/pony-ai-stock-is-up-today-whats-going-on">revealed</a> it had signed a memorandum of understanding with Dubai's Roads and Transport Authority to launch autonomous robotaxi trials later this year, aiming for a full deployment in 2026. 
The move supports Dubai's goal of making 25% of its transportation network autonomous by 2030 and marks another step in Pony.ai's global growth strategy.
Read Also: <a href="https://www.benzinga.com/news/25/05/45677139/boeings-737-max-production-surge-boosts-shares-amid-china-delivery-resumption">Boeing&#8217;s 737 Max Production Surge Boosts Shares Amid China Delivery Resumption</a>
The stock had surged 77% over the past month amid investor enthusiasm surrounding its international deals, including <a href="https://www.benzinga.com/news/25/05/45648859/pony-ai-stock-plunges-wednesday-whats-going-on">recent partnerships</a> with Uber and Tencent, and a 200% year-over-year increase in robotaxi revenue in the first-quarter. The recent declines could reflect profit-taking after the rally, rather than any shift in fundamentals.
Broader sector dynamics may also be contributing to pressure on autonomous vehicle stocks, as competitors like Uber, Lyft and Tesla ramp up full self-driving initiatives. Tesla is <a href="https://www.benzinga.com/tech/25/05/45662671/tesla-targets-june-12-for-robotaxi-launch-in-austin-elon-musk-says-company-ramped-up-fsd-testing-a-month-ahead-of-schedule">preparing</a> to launch a small fleet of driverless Model Ys in Austin within weeks, signaling rising competition in the autonomous mobility space.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/05/45675904/sentinelone-stock-is-falling-thursday-whats-going-on">SentinelOne Stock Is Falling Thursday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy PONY Stock</h2>
By now you're likely curious about how to participate in the market for Pony AI &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Pony AI, which is trading at $17.07 as of publishing time, $100 would buy you 5.86 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PONY has a 52-week high of $23.88 and a 52-week low of $4.11.
Image: Shutterstock

News

PONY

Pony AI Stock Is Selling Off Again: What's Going On?

Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) today confirmed that the Office of the Comptroller of the Currency's 2015 agreements relating to the company's previously held financial subsidiaries have terminated. This is the thirteenth consent order closed by Wells Fargo's regulators since 2019 and the seventh since the beginning of the year. The company's one remaining consent order is the 2018 consent order with the Federal Reserve Board.

Wells Fargo Confirms Termination Of OCC's 2015 Agreements On Financial Subsidiaries

<a href="https://www.bloomberg.com/news/articles/2025-05-29/williams-files-petition-to-revive-new-york-gas-pipeline-project?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-29/williams-files-petition-to-revive-new-york-gas-pipeline-project?embedded-checkout=true</a>

General

'Williams Files Petition to Revive New York Gas Pipeline Project'- Bloomberg

WIIM

Hershey shares are trading higher amid a pullback in cocoa prices.

Israeli multinational pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) hosted 2025 Innovation &amp; Strategy Day on Thursday to launch the acceleration phase of its &#8220;Pivot to Growth&#8221; strategy and to discuss portfolio priorities.
The company outlined its plan to evolve into a leading biopharmaceutical company, emphasizing its innovative medicines franchise and a strong generics and biosimilars portfolio.
President and CEO Richard Francis said the company is entering a new chapter focused on scaling its innovative medicines franchise while maintaining strength in generics and biosimilars.
Francis highlighted that Teva has completed Phase 1 of its "Pivot to Growth" plan, achieving nine consecutive <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45666576/teva-reaffirms-pivot-to-growth-strategy-progress-with-launch-of-acceleration-phase-at-2025-innovat" rel="noreferrer noopener">quarters of growth</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" target="_blank" rel="noreferrer noopener">Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum</a>
The company's innovative medicines portfolio, including Austedo, Ajovy, and Uzedy, generated over $2.3 billion in 2024 revenue.
Teva's generics business has also rebounded, with a 5% increase in revenue across regions and a top-three global portfolio that may yield five new product launches by 2027.
&#8220;The past two years have been about returning to growth&#8230;Now, we are accelerating our growth into a leading biopharma company with a strong innovative medicines franchise and a powerhouse generics and biosimilars portfolio,&#8221; Francis said.
Teva aims to build a $5 billion innovative medicines franchise by 2030, led by its key assets and a strong late-stage pipeline.
Austedo is expected to surpass $2.5 billion in sales by 2027 and reach over $3 billion by 2030. Ajovy is in 43 countries, with additional launches expected this year. Uzedy has rapidly captured over 60% of the risperidone long-acting injectable (LAI) market, and the upcoming olanzapine LAI is expected to expand Teva's footprint in schizophrenia treatment.
The late-stage pipeline includes promising assets such as duvakitug for inflammatory bowel disease, DARI for asthma, and emrusolmin for Multiple System Atrophy, each carrying multibillion-dollar peak sales potential.
TEV-‘408, an anti-IL-15 antibody for celiac disease, has received FDA fast-track status and could exceed $1 billion in peak sales.
Teva's generics, biosimilars, and over-the-counter (OTC) segments remain critical revenue drivers.
The company has 13 biosimilars in development, with five launches planned by 2027. Its $1.1 billion OTC business continues to outperform the market with double-digit growth, while ongoing manufacturing transformations aim to improve competitiveness and margins.
Teva reaffirmed its 2027 financial targets, including a 30% operating margin, more than $2.7 billion in free cash flow, and over $700 million in savings from operational efficiencies.
Price Action: TEVA stock is trading lower by 3.55% to $17.55 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45670275/build-a-bear-sticks-to-outlook-despite-tariff-pressure-stock-soars-25" target="_blank" rel="noreferrer noopener">Build-A-Bear Sticks To Outlook Despite Tariff Pressure, Stock Soars 25%</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

Movers

TEVA

Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030

Rumors

Trading Ideas

GILD

Watching Gilead Sciences; Hearing Investor Business Daily's SwingTrader Buys Stock

New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time
SAN DIEGO, May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4438250-1&amp;h=2291622851&amp;u=https%3A%2F%2Fwww.science.org%2Fdoi%2F10.1126%2Fscience.ads7373&amp;a=published+today">published today</a> in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases. By turning data into insights, this technology is expected to help researchers accelerate new breakthroughs in diagnosis for rare diseases.
Currently, only about 30% of rare disease patients receive an accurate diagnosis from exome sequencing. For many patients, insights may be hidden in what are known as "noncoding regions," which comprise over 98% of the genome and may hold the key to increasing the diagnostic rate.
PromoterAI will be accessible through Illumina Connected Software and it is available today as part of DRAGEN&#x2122; secondary analysis. Precomputed PromoterAI scores for all human promoter single-nucleotide variants are freely available for academic and noncommercial research use. Illumina Connected Software supports seamless integration with next-generation sequencing and array workflows for genomics and multiomics. Researchers, bioinformaticians, and clinical geneticists can use Illumina Connected Software to prioritize variants that are important to a case, gain critical insights, and accelerate their precision medicine dry lab operations.

ILMN

Illumina Unveils PromoterAI, New AI Algorithm That Accurately Deciphers Pathogenic Regulatory Genetic Variants In Noncoding Regions Of Human Genome

<a href="https://www.youtube.com/watch?v=mif6Rc5VBEY">https://www.youtube.com/watch?v=mif6Rc5VBEY</a>

Politics

Economics

Federal Reserve

Fed's Kulger Says Need To Better Understand U.s. Assets' Safe Haven Status; Says 'Keenly Interested' In Connections Between Economy And Commercial Real Estate

Fed's Kulger Does Not Comment On Economic, Monetary Policy Outlook In Opening Remarks To Fed Macro-finance Workshop In Washington; Says Watching To Better Understand Link Between Trade And Market Vulnerability; Says Monitoring Shifts In Possible Lower Demand For U.S. Assets

ROIV

Roivant Sciences shares are trading higher following Q4 reported financial results.

IMVT

Immunovant shares are trading higher following a Q4 EPS beat.

Analysts' ratings for Superior Gr of Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGC#NASDAQ">SGC</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.25, a high estimate of $20.00, and a low estimate of $15.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 17.86%. 
<img src="https://www.benzinga.com/files/images/story/2025/1748541719_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Superior Gr of Cos. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Kupinski</td>
<td>Noble Capital Markets</td>
<td>Announces</td>
<td>Outperform</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Steinke</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Kevin Steinke</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Superior Gr of Cos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Superior Gr of Cos compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Superior Gr of Cos's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Superior Gr of Cos's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SGC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Superior Gr of Cos analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Superior Gr of Cos</h2>
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
<h3>Superior Gr of Cos's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Superior Gr of Cos's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -1.26%. This indicates a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Superior Gr of Cos's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -0.55%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Superior Gr of Cos's ROE stands out, surpassing industry averages. With an impressive ROE of -0.39%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.18%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.54, Superior Gr of Cos adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Superior Gr of Cos: Insights From 4 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Estee Lauder Cos, revealing an average target of $66.64, a high estimate of $90.00, and a low estimate of $55.00. Highlighting a 10.9% decrease, the current average has fallen from the previous average price target of $74.79. 
<img src="https://www.benzinga.com/files/images/story/2025/1748541709_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Estee Lauder Cos. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$63.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$66.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$76.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$62.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$76.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Christopher Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$67.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Estee Lauder Cos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Estee Lauder Cos compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Estee Lauder Cos's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Estee Lauder Cos analyst ratings.</a>
<h2>Unveiling the Story Behind Estee Lauder Cos</h2>
Estée Lauder is a leader in the global prestige beauty market, participating across skin care (51% of fiscal 2024 sales), makeup (29%), fragrance (16%), and hair care (4%) categories, with top-selling brands such as Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 30% of revenue from the Americas, 39% from Europe, the Middle East and Africa (including travel retail), and 31% from Asia-Pacific. Estée Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
<h3>Estee Lauder Cos: Delving into Financials</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Decline in Revenue: Over the 3M period, Estee Lauder Cos faced challenges, resulting in a decline of approximately -9.9% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Estee Lauder Cos's net margin is impressive, surpassing industry averages. With a net margin of 4.48%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Estee Lauder Cos's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.74% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.8%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.16, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Estee Lauder Cos Stock

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XPEV

Shares of USlisted Chinese stocks led are trading higher after a federal court invalidated global tariffs enacted by President Donald Trump under the International Emergency Economic Powers Act on Wednesday.

Throughout the last three months, 12 analysts have evaluated Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Rhythm Pharmaceuticals, presenting an average target of $76.58, a high estimate of $94.00, and a low estimate of $66.00. This current average reflects an increase of 8.13% from the previous average price target of $70.82. 
<img src="https://www.benzinga.com/files/images/story/2025/1748541700_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Rhythm Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$72.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$78.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Rhythm Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Rhythm Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Rhythm Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Rhythm Pharmaceuticals Better</h2>
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
<h3>Financial Insights: Rhythm Pharmaceuticals</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Rhythm Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 25.94% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Rhythm Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -155.39%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -249.88%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Rhythm Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -13.05%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.21, Rhythm Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RYTM

12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know

Dick's Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) reported weaker-than-expected first-quarter 2025 <a href="https://www.benzinga.com/quote/DKS/earnings">results on Wednesday</a>.
The company reported first-quarter adjusted earnings per share of $3.37, missing the analyst consensus estimate of $4.34. Quarterly sales of $3.17 billion (+5.2% year over year) missed the Street view of $3.59 billion.
"Earlier this month, we announced our plans to acquire Foot Locker, a move that represents a truly exciting and transformational moment for Dick's. For many years we've admired Foot Locker's brand and the powerful community they've built in sneaker culture. By bringing our two great brands together, we see the opportunity to create a global leader in the sports retail industry by serving a broader set of athletes," said Ed Stack, executive chairman of Dick's Sporting Goods.
The company maintained its FY2025 sales forecast of $13.60 billion to $13.90 billion, compared with the analyst expectations of $13.86 billion.
It reaffirmed the FY2025 GAAP EPS outlook of $13.80 to $14.40, which includes the expected impact from all tariffs currently in effect.
Dick's shares gained 1.2% to trade at $179.24 on Thursday.
These analysts made changes to their price targets on Dick's following earnings announcement.
<ul class="wp-block-list">
<li>DA Davidson analyst Michael Baker maintained Dick&#8217;s Sporting Goods with a Buy and lowered the price target from $273 to $230.</li>
<li>JP Morgan analyst Christopher Horvers maintained the stock with a Neutral and lowered the price target from $224 to $195.</li>
<li>Barclays analyst Adrienne Yih maintained the stock with an Overweight rating and raised the price target from $217 to $232.</li>
<li>UBS analyst Michael Lasser maintained Dick&#8217;s Sporting Goods with a Buy and lowered the price target from $260 to $225.</li>
</ul>
Considering buying DKS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/DKS/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="608" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29140026/image-396-1024x608.png" alt="" class="wp-image-932036" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29140026/image-396-1024x608.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29140026/image-396-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29140026/image-396-768x456.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29140026/image-396.png 1070w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45667868/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Markets

These Analysts Revise Their Forecasts On Dick's Sporting Goods After Q1 Results

Monro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.8, a high estimate of $21.00, and a low estimate of $15.00. A 14.42% drop is evident in the current average compared to the previous average price target of $20.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1748541685_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Monro is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Lantz</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Lantz</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Thomas Wendler</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Thomas Wendler</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Monro. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Monro compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Monro's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Monro's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MNRO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Monro analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Monro Better</h2>
Monro Inc is a provider automobile service stations in the United States. Through its network of company-owned service stations, Monro Muffler Brake offers maintenance, repair, tire, and fleet management services for automobiles focused largely on undercar services such as brake, steering, exhaust, drivetrain, and suspension systems. Next to service stores, the company also offers tire stores specialised in tire replacement and service.
<h3>Monro's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Monro's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -3.74% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Monro's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.39%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Monro's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.65%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.25%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Monro's debt-to-equity ratio is below the industry average at 0.83, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MNRO

The Analyst Verdict: Monro In The Eyes Of 5 Experts

Investors with a lot of money to spend have taken a bearish stance on Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with META, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 73 uncommon options trades for Meta Platforms.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 41%, bearish.
Out of all of the special options we uncovered, 18 are puts, for a total amount of $2,679,357, and 55 are calls, for a total amount of $4,778,604.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $900.0 for Meta Platforms over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Meta Platforms's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Meta Platforms's whale trades within a strike price range from $5.0 to $900.0 in the last 30 days. 
<h3>Meta Platforms Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748541683_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$119.8</td>
<td>$118.6</td>
<td>$118.9</td>
<td>$710.00</td>
<td>$1.7M</td>
<td>258</td>
<td>150</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$642.5</td>
<td>$639.55</td>
<td>$641.76</td>
<td>$5.00</td>
<td>$641.7K</td>
<td>6.9K</td>
<td>32</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$643.15</td>
<td>$639.1</td>
<td>$641.29</td>
<td>$5.00</td>
<td>$641.2K</td>
<td>6.9K</td>
<td>22</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$641.5</td>
<td>$638.35</td>
<td>$640.16</td>
<td>$5.00</td>
<td>$640.1K</td>
<td>5.1K</td>
<td>10</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$9.5</td>
<td>$9.45</td>
<td>$9.5</td>
<td>$640.00</td>
<td>$191.0K</td>
<td>2.9K</td>
<td>1.6K</td>
</tr>
</tbody>
</table>

<h3>About Meta Platforms</h3>
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.
<h3>Current Position of Meta Platforms</h3>
<ul>
<li>With a volume of 5,577,122, the price of META is up 0.18% at $644.77. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 62 days.</li>
</ul>
<h3>Expert Opinions on Meta Platforms</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $721.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Meta Platforms, targeting a price of $675. 
&#x2A; Maintaining their stance, an analyst from TD Securities continues to hold a Buy rating for Meta Platforms, targeting a price of $700. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Meta Platforms with a target price of $655. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Meta Platforms, targeting a price of $690. 
&#x2A; An analyst from Loop Capital persists with their Buy rating on Meta Platforms, maintaining a target price of $888. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Meta Platforms with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Meta Platforms Unusual Options Activity

Deep-pocketed investors have adopted a bullish approach towards Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BTDR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Bitdeer Technologies. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $432,250, and 8 are calls, amounting to $414,993.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $7.5 to $16.0 for Bitdeer Technologies over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Bitdeer Technologies's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Bitdeer Technologies's substantial trades, within a strike price spectrum from $7.5 to $16.0 over the preceding 30 days.
<h3>Bitdeer Technologies Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748541678_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTDR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.05</td>
<td>$1.0</td>
<td>$1.0</td>
<td>$14.00</td>
<td>$392.2K</td>
<td>3.9K</td>
<td>3.9K</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$0.4</td>
<td>$0.3</td>
<td>$0.4</td>
<td>$16.00</td>
<td>$65.8K</td>
<td>548</td>
<td>3.2K</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.9</td>
<td>$6.8</td>
<td>$6.8</td>
<td>$10.00</td>
<td>$54.4K</td>
<td>7.2K</td>
<td>497</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.8</td>
<td>$6.6</td>
<td>$6.8</td>
<td>$10.00</td>
<td>$54.4K</td>
<td>7.2K</td>
<td>80</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.8</td>
<td>$6.6</td>
<td>$6.8</td>
<td>$10.00</td>
<td>$50.9K</td>
<td>7.2K</td>
<td>205</td>
</tr>
</tbody>
</table>

<h3>About Bitdeer Technologies</h3>
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
In light of the recent options history for Bitdeer Technologies, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Bitdeer Technologies Standing Right Now?</h3>
<ul>
<li>With a volume of 3,297,957, the price of BTDR is up 1.75% at $14.55. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 74 days.</li>
</ul>
<h3>What The Experts Say On Bitdeer Technologies</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $18.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Bitdeer Technologies with a target price of $17. 
&#x2A; An analyst from Rosenblatt persists with their Buy rating on Bitdeer Technologies, maintaining a target price of $20. 
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Buy rating on Bitdeer Technologies with a target price of $15. 
&#x2A; An analyst from B. Riley Securities has decided to maintain their Buy rating on Bitdeer Technologies, which currently sits at a price target of $18. 
&#x2A; Reflecting concerns, an analyst from Benchmark lowers its rating to Buy with a new price target of $24.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bitdeer Technologies options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

BTDR

Check Out What Whales Are Doing With BTDR

Comments

RPAR Risk Parity ETF

Notizie

Ultime notizie per RPAR Risk Parity ETF (ARCA:RPAR)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO